Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 4D Molecular Therapeutics, Inc.

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.